Research Grade Teprotumumab

Catalog #: DHC29903 Specific References (0) DATASHEET

SDS-PAGE for Research Grade Teprotumumab ?>

SEC-HPLC for Research Grade Teprotumumab ?>

Host species: Human

Isotype: IgG1-nd

Applications: Research Grade Biosimilar

Expression system: Mammalian Cells

Overview

Catalog No.

DHC29903

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-nd

Clonality

Monoclonal

Applications

Research Grade Biosimilar

Target

CD221, Insulin-like growth factor 1 receptor, IGF1R, Insulin-like growth factor I receptor, IGF-I receptor

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08069

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

RO4858696-000, CAS: 1036734-93-6

Clone ID

Teprotumumab

Note

For research use only. Not suitable for clinical or therapeutic use.

Data Image

Bioactivity

Detects Human CD221/IGF1R in indirect ELISAs.
SDS-PAGE

SDS PAGE for Teprotumumab
SEC-HPLC

The purity of this product is >95% as determined by SEC-HPLC.
Bioactivity

(C) The mRNA expression levels of IL-6, IL-8, IL-1β, and HAS1 in GOFs stimulated by M22 and treated with aptamer YC3 (2 μM) or Teprotumuab (5 μg/mL) by qPCR, n=3 independent samples in non-stimulated group, n=6 independent samples in M22-stimulated group. Data are represented as mean±SEM. One-way ANOVA, followed by Tukey's multiple post hoc test was used to calculate P values. (D) The concentrations of IL-6, IL-8, IL-1β, and HA in the supernatant medium of GOFs stimulated by M22 and treated with aptamer YC3 (2 μM) or teprotumumab (5 μg/mL) were measured by ELISA, n=3 independent samples in non-stimulated group, n=6 independent samples in M22- stimulated group. Data are represented as mean±SEM. One-way ANOVA, followed by Tukey's multiple post hoc test was used to calculate P values.
Data sourced from citation (PMID: 41054857)
Bioactivity

Figure 6. YC3 attenuates disease-associated phenotypes in orbital fibroblasts. D) The mRNA expression levels of IL-6, IL-8, IL-1𝛽, and HAS1 in GOFs stimulated by M22 and treated with aptamer YC3 (2 μM) or Teprotumumab (5 μg mL−1) by qPCR, n = 3 independent samples in the non-stimulated group, n = 6 independent samples in the M22-stimulated group. E) The concentrations of IL-6, IL-8, IL-1𝛽, and HA in the supernatant medium of GOFs stimulated by M22 and treated with either aptamer YC3 (2 μM) or Teprotumumab (5 μg mL−1) were measured by ELISA, n = 3 independent samples in the non-stimulated group, n = 6 independent samples in the M22-stimulated group.
Data sourced from citation (PMID: 41054857)

References

Datasheet

Document Download

Research Grade Teprotumumab.pdf

$ 280

Product specifications

1 mg 280 5 mg 840 25 mg 2350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here